|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1996013593A2
(en)
|
1994-10-26 |
1996-05-09 |
Procept, Inc. |
Soluble single chain t cell receptors
|
|
WO1996018105A1
(en)
|
1994-12-06 |
1996-06-13 |
The President And Fellows Of Harvard College |
Single chain t-cell receptor
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
|
WO1999018129A1
(en)
|
1997-10-02 |
1999-04-15 |
Sunol Molecular Corporation |
Soluble single-chain t-cell receptor proteins
|
|
WO1999060120A2
(en)
|
1998-05-19 |
1999-11-25 |
Avidex Limited |
Soluble t cell receptor
|
|
JP2002524081A
(ja)
|
1998-09-04 |
2002-08-06 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
前立腺−特異的膜抗原に特異的な融合受容体およびその使用
|
|
WO2000023573A2
(en)
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6940003B1
(en)
*
|
1998-12-03 |
2005-09-06 |
E. I. Du Pont De Nemours And Company |
Plan lecithin: cholesterol acyltransferases
|
|
GB9912350D0
(en)
|
1999-05-26 |
1999-07-28 |
European Molecular Biology Lab Embl |
Modified cytokine
|
|
NZ520379A
(en)
|
1999-12-30 |
2004-05-28 |
Chiron Corp |
Methods for administrering interleukin-2 by pulmonary inhalation
|
|
US20020131960A1
(en)
|
2000-06-02 |
2002-09-19 |
Michel Sadelain |
Artificial antigen presenting cells and methods of use thereof
|
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
FI117667B
(fi)
|
2001-07-05 |
2007-01-15 |
Univ Zuerich |
Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
|
|
AU2002321581C1
(en)
|
2001-08-31 |
2008-09-18 |
Adaptimmune Limited |
Soluble T cell receptor
|
|
US7205275B2
(en)
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
|
DK1451322T3
(da)
|
2001-11-05 |
2010-02-01 |
Zymogenetics Inc |
Il-21-antagonister
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
AU2003271904B2
(en)
|
2002-10-09 |
2009-03-05 |
Adaptimmune Limited |
Single chain recombinant T cell receptors
|
|
DE60327795D1
(de)
|
2002-11-09 |
2009-07-09 |
Immunocore Ltd |
T zell rezeptor "display"
|
|
WO2004044006A1
(en)
|
2002-11-14 |
2004-05-27 |
Maxygen, Inc. |
Conjugates of interleukin-10 and polymers
|
|
GB0304068D0
(en)
|
2003-02-22 |
2003-03-26 |
Avidex Ltd |
Substances
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
US7276478B2
(en)
|
2003-09-25 |
2007-10-02 |
Zymogenetics, Inc. |
Methods of treating autoimmune diseases using IL-21
|
|
DK1765860T3
(da)
|
2004-05-19 |
2009-03-09 |
Immunocore Ltd |
Ny-ESO-T.cellereceptor med höj affinitet
|
|
NZ550815A
(en)
|
2004-05-19 |
2009-04-30 |
Immunocore Ltd |
Method of improving T cell receptors
|
|
US8361794B2
(en)
|
2004-06-29 |
2013-01-29 |
Immunocore Limited |
Cells expressing a modified T cell receptor
|
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
AU2006237329B2
(en)
|
2005-04-18 |
2012-04-12 |
Novo Nordisk A/S |
IL-21 variants
|
|
WO2006125962A2
(en)
|
2005-05-25 |
2006-11-30 |
Medigene Limited |
T cell receptors which specifically bind to vygfvracl-hla-a24
|
|
US8871912B2
(en)
|
2006-03-24 |
2014-10-28 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
WO2008039818A2
(en)
|
2006-09-26 |
2008-04-03 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
|
EP2087000A2
(en)
|
2006-09-29 |
2009-08-12 |
Immunocore Ltd. |
T cell therapies
|
|
CA2671665A1
(en)
|
2006-12-21 |
2008-06-26 |
Novo-Nordisk A/S |
Interleukin-21 variants with altered binding to the il-21 receptor
|
|
CA2682527C
(en)
|
2007-03-30 |
2017-07-11 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
|
US20120164718A1
(en)
|
2008-05-06 |
2012-06-28 |
Innovative Micro Technology |
Removable/disposable apparatus for MEMS particle sorting device
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
|
JP2012510806A
(ja)
|
2008-12-08 |
2012-05-17 |
コンプリクス エン ヴェー |
単鎖逆平行コイルドコイルタンパク質
|
|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
|
EP2406282A1
(en)
|
2009-03-11 |
2012-01-18 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
CA2777053A1
(en)
|
2009-10-06 |
2011-04-14 |
The Board Of Trustees Of The University Of Illinois |
Human single-chain t cell receptors
|
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
|
EP3459564B1
(en)
*
|
2010-01-06 |
2021-10-27 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein binding proteins
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
MX2013009151A
(es)
|
2011-02-10 |
2013-08-29 |
Roche Glycart Ag |
Inmunoterapia mejorada.
|
|
CN110200997A
(zh)
|
2011-03-23 |
2019-09-06 |
弗雷德哈钦森癌症研究中心 |
用于细胞免疫治疗的方法和组合物
|
|
EA201892619A1
(ru)
*
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
|
KR102134932B1
(ko)
|
2011-11-11 |
2020-07-17 |
프레드 헛친슨 켄서 리서치 센터 |
암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법
|
|
JP6850528B2
(ja)
|
2012-02-13 |
2021-03-31 |
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート |
二重特異性キメラ抗原受容体およびその治療的使用
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
SG10201609210SA
(en)
|
2012-05-03 |
2016-12-29 |
Hutchinson Fred Cancer Res |
Enhanced affinity t cell receptors and methods for making the same
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
EP2861617A1
(en)
*
|
2012-06-15 |
2015-04-22 |
Pfizer Inc. |
Improved antagonist antibodies against gdf-8 and uses therefor
|
|
AR092044A1
(es)
|
2012-08-07 |
2015-03-18 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
|
EP2882775B1
(en)
*
|
2012-08-09 |
2018-02-14 |
Roche Glycart AG |
Asgpr antibodies and uses thereof
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
CA2881981A1
(en)
|
2012-08-20 |
2014-02-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
AU2013327136A1
(en)
|
2012-10-02 |
2015-04-16 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
CN104271602B
(zh)
|
2012-11-21 |
2020-08-21 |
武汉友芝友生物制药有限公司 |
双特异性抗体
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
KR102042246B1
(ko)
|
2014-02-06 |
2019-11-28 |
에프. 호프만-라 로슈 아게 |
인터류킨-2 융합 단백질 및 이의 용도
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
GB2538666A
(en)
|
2014-07-21 |
2016-11-23 |
Delinia Inc |
Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
JO3568B1
(ar)
*
|
2014-09-05 |
2020-07-05 |
Janssen Pharmaceutica Nv |
عوامل ربط cd123 واستخداماتها
|
|
EP3875152B1
(en)
|
2014-12-15 |
2024-04-10 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
WO2017027422A1
(en)
|
2015-08-07 |
2017-02-16 |
Alexo Therapeutics Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
KR102095096B1
(ko)
|
2015-08-26 |
2020-03-30 |
바이슨 테라퓨틱스 인크. |
다중특이적 항체 플랫폼 및 관련 방법
|
|
RU2767329C2
(ru)
|
2016-02-06 |
2022-03-17 |
Эпимаб Биотерапьютикс, Инк. |
Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
|
|
KR102687530B1
(ko)
|
2016-05-04 |
2024-07-25 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
US11077172B2
(en)
|
2016-11-08 |
2021-08-03 |
Delinia, Inc. |
IL-2 variants for the treatment of psoriasis
|
|
CU24483B1
(es)
|
2016-11-15 |
2020-04-02 |
Ct Inmunologia Molecular |
Método para incrementar los niveles de secreción de la interleucina-2
|
|
US20200078401A1
(en)
|
2016-12-07 |
2020-03-12 |
La Jolla Institute For Allergy And Immunology |
Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
|
|
CN116970059A
(zh)
|
2016-12-22 |
2023-10-31 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
EP3565638B8
(en)
|
2017-01-06 |
2024-04-10 |
BicycleRD Limited |
Bicycle conjugate for treating cancer
|
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
RU2761377C2
(ru)
|
2017-04-03 |
2021-12-07 |
Ф. Хоффманн-Ля Рош Аг |
Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
|
|
US20200224161A1
(en)
|
2017-05-10 |
2020-07-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
JP2020521452A
(ja)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
標的化免疫寛容
|
|
EP3635097A1
(en)
|
2017-06-05 |
2020-04-15 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
US11202493B2
(en)
|
2017-06-23 |
2021-12-21 |
Glo-One Co., Ltd. |
Asymmetrical structure moisturizing mask pack
|
|
US20210017247A1
(en)
|
2017-07-03 |
2021-01-21 |
Torque Therapeutics, Inc. |
Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
|
|
KR102880156B1
(ko)
*
|
2017-07-24 |
2025-11-05 |
리제너론 파마슈티칼스 인코포레이티드 |
항cd8 항체 및 이의 용도
|
|
IL316357A
(en)
*
|
2017-07-31 |
2024-12-01 |
Trishula Therapeutics Inc |
Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
|
|
DK3661954T3
(da)
|
2017-08-03 |
2022-04-19 |
Amgen Inc |
Interleukin-21-muteiner og fremgangsmåder til behandling
|
|
EP3672990A1
(en)
*
|
2017-08-25 |
2020-07-01 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
|
EP3676289B1
(en)
|
2017-08-28 |
2026-03-04 |
Altor BioScience, LLC |
Il-15-based fusions to il-7 and il-21
|
|
CN111527109B
(zh)
|
2017-12-26 |
2024-11-01 |
南京金斯瑞生物科技有限公司 |
以抗体Fc区为骨架的融合蛋白二聚体及其应用
|
|
TW201930344A
(zh)
|
2018-01-12 |
2019-08-01 |
美商安進公司 |
抗ｐｄ-１抗體及治療方法
|
|
AU2019212709A1
(en)
|
2018-01-26 |
2020-08-13 |
Genentech, Inc. |
IL-22 Fc fusion proteins and methods of use
|
|
JP2021516045A
(ja)
|
2018-02-28 |
2021-07-01 |
ファイザー・インク |
Ｉｌ−１５バリアントおよびその使用
|
|
US20210024631A1
(en)
|
2018-03-28 |
2021-01-28 |
Orionis Biosciences, Inc. |
Bi-functional proteins and construction thereof
|
|
AU2018418224B2
(en)
*
|
2018-04-09 |
2025-04-17 |
Oricell Therapeutics Co., Ltd. |
Anti-PD-L1 antibody and use thereof
|
|
EP3810624A4
(en)
|
2018-06-22 |
2022-07-06 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
JP7637415B2
(ja)
|
2018-06-22 |
2025-02-28 |
キュージーン インコーポレイテッド |
インターロイキン－２バリアントおよびその使用方法
|
|
MX2021000801A
(es)
|
2018-07-24 |
2021-04-12 |
BioNTech SE |
Agonistas de il2.
|
|
US12459980B2
(en)
|
2018-07-25 |
2025-11-04 |
AskGene Pharma, Inc. |
IL-21 prodrugs and methods of use thereof
|
|
HRP20240016T1
(hr)
|
2018-09-11 |
2024-03-29 |
Ambrx, Inc. |
Konjugati polipeptida interleukina-2 i njihove uporabe
|
|
WO2020057646A1
(zh)
|
2018-09-21 |
2020-03-26 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
EP3854805A4
(en)
|
2018-09-21 |
2022-08-24 |
Innovent Biologics (Suzhou) Co., Ltd. |
NOVEL INTERLEUKIN 2 AND ITS USE
|
|
WO2020082057A1
(en)
|
2018-10-19 |
2020-04-23 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
|
US12378295B2
(en)
|
2018-10-29 |
2025-08-05 |
1Globe Biomedical Co., Ltd. |
Rationally designed protein compositions
|
|
ES3059360T3
(en)
|
2018-11-08 |
2026-03-19 |
Synthorx Inc |
Interleukin 10 conjugates and uses thereof
|
|
US20220025007A1
(en)
|
2018-12-21 |
2022-01-27 |
Hanmi Pharm. Co., Ltd. |
Novel immunosuppressive interleukin 2
|
|
KR20210113265A
(ko)
|
2019-01-07 |
2021-09-15 |
인히브릭스, 인크. |
변형된 il-2 폴리펩타이드를 포함하는 폴리펩타이드 및 이의 용도
|
|
GB201900732D0
(en)
*
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
|
AU2020287373B2
(en)
|
2019-06-05 |
2026-01-29 |
Asher Biotherapeutics, Inc. |
Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
TW202216745A
(zh)
|
2020-07-02 |
2022-05-01 |
美商英伊布里克斯公司 |
包含經修飾ｉｌ－２多肽之多肽及其用途
|
|
TW202231292A
(zh)
|
2020-10-13 |
2022-08-16 |
美商健生生物科技公司 |
用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
|
|
WO2022125712A1
(en)
*
|
2020-12-09 |
2022-06-16 |
Asher Biotherapeutics, Inc. |
Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
|
|
CN116829194A
(zh)
|
2020-12-09 |
2023-09-29 |
亚设生物治疗公司 |
用于工程化细胞疗法的靶向细胞因子构建体
|
|
EP4273158A1
(en)
|
2020-12-23 |
2023-11-08 |
Innovent Biologics (Suzhou) Co., Ltd. |
Interleukin-21 mutant and use thereof
|
|
AU2022275666A1
(en)
|
2021-05-19 |
2023-12-07 |
Asher Biotherapeutics, Inc. |
Il-21 polypeptides and targeted constructs
|
|
KR20230044130A
(ko)
|
2021-09-24 |
2023-04-03 |
바이오엔시스템스 주식회사 |
Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도
|
|
MX2024003889A
(es)
|
2021-09-30 |
2024-04-22 |
Yunovia Co Ltd |
Inmunocitocina que contiene la muteina de il-21r.
|
|
JP2025515470A
(ja)
|
2022-04-27 |
2025-05-15 |
アシャ バイオセラピューティクス，インク． |
サイトカイン融合タンパク質とｃｄ８抗原結合分子の併用
|